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This thesis work includes three projects. First part deals with the investigation of novel D2 
receptor ligands in Prepulse inhibition. The goal of this study is to establish a relationship 
between dopamine receptor antagonists and agonists and prepulse inhibition which can 
then serve as a working model for an in-vivo efficacy of novel dopamine D2 drugs. The 
second part of the thesis work deals with Niemann pick disease type C. Niemann pick 
disease type C is a progressive genetic disorder that is characterized by the lysosomal 
accumulation of lipids which causes neurodegeneration, dementia, ataxia, and death. 
NPC1nmf164 mutant mice (knockout) have a delayed acquisition of motor skills during 
development. The aim of our study was to identify cellular and molecular pathways 
involved in causing and progressing NPC in young patients from which effective 
therapeutic interventions can be designed and tested to prevent or delay the onset of the 
disease and prolong and improve the quality of life of young NPC patients.Finally, the last 
part of this thesis work includes studies on synergistic anithyperalgesic and antinociceptive 
effects of morphine and MP-III-024, a positive allosteric modulator at α2 GABAA and 
α3GABAA receptors. The purpose of this study was to examine the interactive effects of 
the μ-opioid agonist morphine and the α2GABAA and α3GABAA receptor positive 
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Investigating Novel Dopamine D2 Receptor Ligands in Prepulse Inhibition 
Introduction 
 Prepulse inhibition is the reduction in startle amplitude to an acoustic startle stimulus 
when preceded by a weaker pre-stimulus within a certain time frame (fig.1). The 
information processing begins during the initial 100ms following the onset of a stimuli 
with a set of preattentional automatic processes in organisms with complex nervous 
systems that trigger different response mechanisms, one among which is the startle 
response, a neuronal reflex mechanism that prepares an organism to face a potentially 
relevant stimulus. Therefore, acoustic startle response is a protective mechanism that is 
elicited by a sudden and intense acoustic stimulus1. PPI is normal in healthy individuals 
but impaired in patients with schizophrenia and Alzheimer’s disease due to abnormalities 
in sensorimotor gating. Commercially available drugs used in the treatment of psychotic 
disorders, such as the dopamine D2 receptor antagonist haloperidol, increase PPI. The 
goal of this study is to establish a relationship between dopamine receptor antagonists 
and agonists and prepulse inhibition which can then serve as a working model for an in-
vivo efficacy of novel dopamine D2 drugs.  
Reflex and Its Importance 
Reflex is an involuntary movement that arises in response to a peripheral stimulus 
and gets conducted to the nerve center in the brain or spinal cord. Spinal cord is an abode 




groups of muscles. The reflex begins in an impulse upon the stimulation of a sensory or 
afferent nerve. It is conducted to the center in the spinal cord, from the sensory cell bodies 
to the neurons of the corresponding motor center. As a result, a motor impulse originates 
in the motor nerve which then is transmitted to the muscle fibers that are supplied by the 
nerve. This complete path is called as a reflex arc. A reflex arc is complicated when sensory 
impulses are conducted to the higher or lower-level centers and excite several motor 
impulses. If the arc, either in its sensory or motor limb or in the center, is interrupted, the 
reflex is lost. Spinal reflexes are very important for survival and include the stretch reflex, 
the Golgi tendon reflex, the crossed extensor reflex, and the withdrawal reflex3.  
The stretch reflex, also called a myotatic reflex is a monosynaptic reflex that causes muscle 
contraction in response to stretch within the muscle. These are the shortest latency reflexes 
as they travel the shortest distance between the muscle and spinal cord and from the same 
segment of the spinal cord that it entered to the muscle. The knee jerk reflex is an example 
of a stretch reflex3.  
Golgi Tendon reflex is a negative feedback mechanism that prevents the tendon from 
breaking due to muscle force by causing muscle relaxation2. As tension builds in the 
tendon, the Golgi tendon organ gets stimulated and propagates nerve impulses along the 
sensory neurons into the spinal cord where it synapses with and activates an inhibitory 
interneuron that releases the neurotransmitter glycine and inhibits the α motor neuron, a 
neuron that innervates extrafusal muscle fibers of skeletal muscle and initiate contraction3.  
Crossed extensor reflex is a contralateral stimulus that occurs on the opposite side of the 




contralateral side of the spinal cord from the stimulated side of the body and synapse with 
and inhibit the alpha motor neurons that innervate the muscles of the contralateral limb. 
An example of this reflex action is when a person steps on a nail. The painful stimulus 
propagates and causes the flexors of the ipsilateral leg (the one that experiences the 
stimulus) to contract and extensors to relax. On the contralateral leg (the other leg that bears 
the weight of the body) the flexors relax and the extensors contract to support the weight 
of the body3.  
Withdrawal reflex is a protective reflex that protects the body from damaging stimuli. It is 
polysynaptic and an example is when a person withdraws his hand from a hot object even 
without consciously wanting to do so. The sensory neurons get stimulated by the receptors 
that receive heat and synapse with the interneurons that relay message to the motor neurons. 
The motor neurons that innervate flexors allow them to withdraw from the stimulus3.  
A reflex need to be sufficiently constant and noticeable to give importance to its alterations, 
particularly in case of its absence, in normal subjects. Reflexes of the lower extremity are 
more vital than those of the upper extremity and knee-jerk is the prominent among them. 
Babinski reflex, ankle clonus, Achilles jerk, abdominal reflex, the cremasteric or inguinal 
reflex, epigastric reflex, and planter reflex etc., are some of the other reflexes that are 
important. Absent or diminished or exaggerated reflexes are indicative of diseases of the 






Startle Reflex  
The startle reflex response is induced by stimuli of adequate intensity reflecting the 
activation of motor paths in the bulbopontine reticular formation of the brainstem. Within 
a few milliseconds, facial and skeletal muscles are activated, leading the whole body to 
flinch in rodents due to changes in the electrical activity. In rats, the startle response can 
be observed within 5msec in the neck and 8msec in the hindleg. Neural pathways mediate 
this acoustic startle response attributing to its very short latency. According to Davis et al., 
the acoustic startle response in the rat is mediated by three synapses-: 1) cochlear root 
neurons; -, 2) neurons in the nucleus reticularis pontis caudalis and 3) motoneurons in the 










Neural Pathway for Acoustic Startle Response  
The neural pathway for Acoustic Startle Response begins in the cochlear nucleus 
upon receiving the stimulus. This signal is transferred to the cells in the nucleus reticularis 
pontis caudalis (PnC) located in the pons of the brainstem which then reaches the reticular 
formation neurons that form circuits with the motor neurons of spinal cord or facial motor 
neurons which control the muscle movements (fig.2)2,3. This causes the startle response6. 
The startle response is adaptive in nature in terms of its plasticity in response that it can be 
either be high or low depending on the intensity of the stimulus produced and the 
circumstances. For instance, when the organism is in a state of emotional activation the 
startle response is augmented because of a non-associative learning process called 
sensitization or attenuated due to a process called habituation, which is because of repeated 
presentations of stimulus. The other circumstance in which the startle reflex is decreased 
is when presented with a low intensity stimulus before a startle stimulus, a process known 



















Prepulse Inhibition, Sensorimotor Gating, and Schizophrenia 
Prepulse inhibition plays a key role in filtering relevant and irrelevant sensory 
information, alteration of which causes an overload of sensory information and can be used 
as a measure of sensorimotor signaling which is impaired in patients with 
Schizophrenia1fig.3). Several studies confirmed the presence of PPI disruption in 
schizophrenia spectrum patients and in other disorders with disrupted gating mechanisms 
which in healthy people involves an integrated symphonic array of time-coordinated events 
across multiple sites that are brought about by a cascade of neurons in multiple loci. Thus, 
PPI is considered as an operational measure of sensorimotor gating which gates out of 
awareness the excess or insignificant stimuli, so that an individual can focus on the most 




gating to describe the construct calculated by PPI because it is involved in the weak sensory 
event or stimulus (the prepulse) inhibiting (or gating) the startle motor response to a 
startling event or stimulus7. 
 
 
Figure 3  




Animal studies suggest that PPI can be because of the descending forebrain circuitry of 
cortico-striato-pallido-pontine (CSPP) interconnected substrates. The regulatory tone is 
transmitted by the pedunculopontine nucleus from the forebrain via descending ventral 
projections from ventral pallidum to the primary startle circuitry thus altering the inhibitory 
effect of the prepulse stimulus on startle reflex. The psychopathological manifestations 




associated with the disease symptoms. Sensorimotor signaling is further influenced by any 
structural abnormalities in the brain regions related directly or indirectly to PPI regulation8.  
Literature has constantly demonstrated the reduction in prepulse inhibition in patients with 
schizophrenia compared to healthy subjects and has thus proposed PPI as a biomarker of 
the disease1.  
Schizophrenia 
It is a serious psychotic illness characterized by an array of symptoms that can be 
categorized into positive, negative and cognitive symptoms, which when left untreated can 
be persistent and disabling. Positive symptoms include hallucinations, delusions and 
thought disorder. Negative symptoms include avolition, anhedonia, flat affect and reduced 
speaking. Cognitive symptoms of schizophrenia are subtle in some patients while in others 
they are more prominent and include difficulty in decision making, paying attention, and 
learning new things9. There are several theories as to what causes schizophrenia that center 
on either an excess or a deficiency of neurotransmitters such as dopamine, serotonin, or 
glutamate. 
Dopamine Hypothesis of Schizophrenia 
 It is the widely accepted theory, and it involves four dopaminergic pathways 
(fig.4). The low dopamine levels within the nigrostriatal pathway that extends from the 
substantia nigra to caudate nucleus is responsible for motor symptoms. Excess dopamine 
levels in the mesolimbic pathway that originates from the ventral tegmental area (VTA) 




and cognitive deficits in schizophrenia are caused by dopamine levels in the mesocortical 
pathway that extends from the VTA to the cortex. The decrease or blockade dopamine 
levels in tuberoinfundibular pathway extending from the hypothalamus to the pituitary 



















Role of Dopamine Receptors. Heightened D2 receptor activation due to increased 
subcortical release of dopamine is responsible for the positive symptoms and reduced D1 
receptor activation in the prefrontal cortex for the negative symptoms of schizophrenia11. 
Serotonin Hypothesis of Schizophrenia 
This hypothesis was developed when a structural similarity between serotonin (5-
hydroxytryptamine; 5HT) and lysergic acid diethylamide (LSD), a hallucinogenic drug, 
was established 40 years ago12. Drugs that blocked both dopamine and serotonin instead of 
just dopamine were found to be more effective in alleviating both positive and negative 
symptoms of schizophrenia11.  
Glutamate Hypothesis of Schizophrenia 
This theory is centered on the lack of glutamate, an excitatory neurotransmitter, 
activity at the NMDA receptor. Increased co-agonists at NMDA receptor showed some 
efficacy in clinical trials in schizophrenic subjects but not yet firmly established13.   
Prepulse Inhibition and Other Psychiatric Disorders 
Prepulse inhibition is deficient in patients with Huntington’s disease, obsessive 
compulsive disorder, nocturnal enuresis, bipolar disorder, Asperger’s syndrome, fragile X 
syndrome, 22q11 syndrome, Alzheimer’s disease, blepharospasm, and Tourette 
syndrome14. Studies in OCD patients revealed dysfunctional PPI which was hypothesized 
to be due to abnormalities in striatal regions and sensorimotor gating. In another study, it 





Huntington’s disease is a genetic neurodegenerative disorder that causes progressive 
breakdown of nerve cells in the brain. Patients with HD have movement abnormalities, 
cognitive impairments, and emotional disturbances16.  Corpus striatum plays an important 
role in inhibiting involuntary and intrusive movements. Degeneration of striatum in 
Huntington’s disease causes a loss of motor inhibition which is manifested as abnormal 
involuntary choreiform movements. Sensorimotor abnormalities or inhibition in such 
patients can be measured using startle reflex17. 
Bipolar disorder shows similar psychotic symptoms as schizophrenia such as 
hallucinations and delusions. Deficits of PPI in bipolar disorder patients were like the 
deficits in schizophrenia. Studies suggested that active manic symptoms and acute 
psychosis might be responsible for PPI dysfunction in bipolar patients18.  
Patients with major depressive disorder showed lower PPI values compared to the control 
subjects in research studies but the impairment was not as profound as was observed in 
patients with psychotic symptoms19.  
Alzheimer’s disease is a progressive neurodegenerative disease that is characterized by 
cognitive and memory deficits due to the structural and functional abnormalities including 
neurofibrillary tangles, amyloid-β accumulation and neuron loss. Decreased prepulse 
inhibition and increased latency to startle was observed in the transgenic mouse model 
Tg4-4220. 
Post-traumatic stress disorder is a condition that develops in people who have experienced 




an increased baseline startle amplitude. PPI in PTSD patients isn’t quite conclusive yet due 
to controversial results. Also, the causes of altered PPI values must be assessed with further 
caution as baseline startle amplitude is elevated in the patients21.  
Niemann Pick Disease Type C is a progressive genetic disorder characterized by the 
lysosomal accumulation of lipids which causes neurodegeneration, dementia, ataxia, and 
death. In some cases of adult-onset NPC, psychiatric disorders such as schizophrenia, 
attention deficit hyperactivity disorder, and depression were pre-diagnosed suggesting 
neural circuitry dysfunction precede the neurological symptoms. So, PPI can be used as a 
diagnostic tool in NPC disease. 
PPI in Previous Studies 
PPI has been effectively studied in various neurological disorders, drug-challenge 
studies and in studies of antipsychotic drug efficacy22. Studies were conducted to determine 
the role of dopamine in prepulse inhibition of acoustic startle response and behavioral 
variations among different genetic strains of mice23. Studies were also conducted to 
determine a relationship between dopamine drugs and prepulse inhibition. Amphetamine, 
an indirect dopamine agonist, was shown to decrease prepulse inhibition by increasing 
dopamine overflow in nucleus accumbens markedly in one study while in the other 
experiment, a combined treatment with subthreshold doses of SKF38393 and quinpirole, 
selective dopamine D1 agonist and a selective dopamine D2 agonist, respectively, decrease 
prepulse inhibition. Lastly, raclopride, a selective dopamine D2/D3 antagonist was shown 




Parametric Effects on PPI 
Prepulse 
 For the prepulse stimulus to inhibit startle response, it must precede the startle 
stimulus by 30-500ms25. The stronger the prepulse stimuli the greater the Prepulse 
Inhibition. In spite of this general rule, prepulse inhibition is not as straightforward as it 
might appear at first. There is more than one factor on which the prepulse inhibition 
depends, one among them being the background noise. The background noise is the 
constant source of sound that is neither the prepulse nor the startle stimulus. Prepulse 
stimulus arising from an uncontrolled ambient background does not elicit a reliable 
relationship between prepulse and startle stimuli and sensorimotor gating as the exact same 
brain processes are not involved in regulating prepulse inhibition arising from different 
background noise levels25. The other factor on which the prepulse inhibition depends is the 
prepulse duration. Bloch’s law stipulates that the stimulus salience reflects an interaction 
of intensity and duration.  
Prepulse-to-Pulse Intervals 
 Interstimulus interval (ISI), the onset of prepulse to the onset of pulse or startle 
stimuli, for eliciting PPI normally ranges from 30 to 240 ms. ISI of 1000ms or more can 
cause facilitation of the startle response magnitude in humans. Thus, in order to assess both 
PPI and facilitation in a single experiment or a session, short and long ISIs can be used 
respectively. In addition to the magnitude of the startle response, the pre-stimulus effects 




and latency-to-startle peak are measures of the rapidity with which the startling stimulus 
evokes the startling response25.  
Inter-Trial Intervals 
 Inter-trial intervals (ITI) lie within a range of 8-30 or more seconds with a range 
centered around 15-20 seconds. Compared to fixed ITIs, variable ITIs causes less 
habituation of startle reflex responses habituation and are thus more favorable for testing25. 
Prepulse Type 
 Discrete white noise prepulses were observed to have maximal PPI effects in both 
normal comparison subjects and schizophrenics in various studies25.  
Aim 
The main aim of the present study was to establish a working model that helps in 
the discovery of effective novel dopamine drugs that can treat various psychoses. Tests 
were conducted on two different strains of mice, all male, using haloperidol, a dopamine 
receptor antagonist to demonstrate its effects on prepulse inhibition13.  
Materials and Methods 
Two different strains of mice, C57BL/6J and CD1, weighing 23–30 g at the start of 
experiments were used. The C57BL/6J mice were obtained from Charles River 
Laboratories (Wilmington, MA) and were housed in a room that was maintained at a 
constant temperature at 21-23°C and humidity at 45-50% at a vivarium located in Cooper 




animals were kept under a 12h light/dark cycle (lights on at 0700 and off at 1900) in groups 
of four per cage in polycarbonate cages with ad libitum food and water and enrichment 
provided by paper Bio-Huts and/or nestlets. The mice were weighed and marked almost 
every morning over the period of the research and monitored for general health and 
behavioral parameters.  
Animals  
C57BL/6J 
 These are widely used in several different research studies because of their 
availability and robustness. C57BL/6J are inbred mice strain developed by C. C. Little in 
1921 which were handed over to Charles River in 1974 from NIH26. Also known as B6, 
B6/J mice, C57BL/6J mice are used mainly in research areas like cardiovascular biology, 
developmental biology, diabetes and obesity, immunology, genetics, and sensorimotor 
research. Their preference for alcohol and morphine and sensitivity to noise and odors 
make them the best fit for addiction and prepulse inhibition studies27. C57BL/6J’s are deep 
brown to black in color with a tendency to bite. The dominant mice tend to remove hair 
and whiskers of cage mates28.  
CD1 
 These are the most popular strain of the outbred mice that are used in toxicology 
and pharmacology research. The CD1 IGS mice are albino (have completely white hair) 




They are docile and easy to handle compared to other types and display minimal evasive, 
struggling, and aggressive behavior when caught and held29.  
Drugs 
Haloperidol was obtained from Sigma Aldrich, (St. Louis, MO, USA). It is a white 
to faintly yellowish amorphous or micro-crystalline powder. It is poorly soluble in water 
but freely soluble in chloroform, methanol, acetone, benzene, and dilute acids30. 
Haloperidol is a first-generation butyrophenone antipsychotic drug active at postsynaptic 
dopamine (D2, D3, and D4) receptors in the mesolimbic system of the brain. It is effective 
in the management of the positive symptoms of Schizophrenia such as hallucinations, 
delusions, hearing voices, aggression/hostility, disorganized speech, and psychomotor 
agitation. Haloperidol along with other first-generation antipsychotics has side effects of 
tardive dyskinesia, drug induced Parkinsonism, sedation, and weight gain31.  
Three different doses, 0.1mg/kg, 0.3mg/kg, and 1mgkg, and a vehicle dose of haloperidol 
were used in this study. The drug, 0.1N HCl and DMSO were vortexed until the drug 















A Med-associates apparatus was used. The mouse was held in a restraining tube 
attached to a movement-sensitive plate and screwed onto a platform table in a sound 
attenuating cubicle. To ensure proper functioning of the system, both the sound attenuating 
chambers were calibrated using the “calibrate audio” utility and the ANL-929A-PC USB 
microphone package17. Acoustic startle and prepulse stimuli were produced by a speaker 
that fit snugly inside the chamber. The analog-to-digital converter converts the analog 







Two strains of mice, C57 and CD1, each with a different protocol were tested in 
PPI. Two different software were used; Startle reflex, which is a manual setup software 
and Startle pro, which is a highly automated software.  
Startle Reflex Software 
The pilot testing in C57 mice was divided into an initial acclimation period and 
Block I startle only period with 6 trials, Block II prepulse plus startle period with 30 trials, 
and Block III startle only period with 6 trials. Six different startle intensities between 95dBs 
and 120dBs and five different prepulse intensities between 70-100 dB with rise/fall time 
of 1 ms and 0 ms respectively and a 100 ms prepulse/startle delay were tested. In the next 
stage, the same procedure with 0.1mg/kg, 0.3mg/kg, and 1mg/kg, doses of haloperidol or 
vehicle (95% saline, 5% DMSO, 1N HCl) was tested. This protocol had two main 
drawbacks. Firstly, prepulse noise levels itself caused startle in the animals. Secondly, the 
drug solution caused ulcers at the site of injection and severe catalepsy which led to the 
death of many mice. The testing was later carried out in cd1 mice with a modified protocol. 
Initially, all the animals were acclimated to 70 dBs of white background noise for 15 
minutes for three consecutive days. The next three days animals were subjected to varying 
startle levels of 70 dB, 80 dB, 90 dB, and 100 dB. In the next stage, experiments were 
conducted at four different startle intensities as in the previous step along with a prepulse 
level of 70 dBs at three different frequencies of 4000 Hz, 12000 Hz, and 20000 Hz with 
rise/fall time of 0ms and 3ms respectively and prepulse/startle delay of 100ms9. The testing 




noise. All the blocks had 18trials with both prepulse and startle stimuli. Prepulse 
frequencies for block I, II, and III were set to 4000 Hz, 12,000 Hz, and 20,000 Hz, 
respectively. In the next step, the same procedure was followed with 0.1 mg/kg, 0.3 mg/kg, 
1 mg/kg doses of haloperidol or vehicle. Open field tests were conducted simultaneously 
to study the effect of drug on locomotor properties of mice.  
Startle PPI Software 
8 Cd1 mice were used for testing in this procedure. Animals were initially 
acclimated to the chambers for three days with constant white background noise at 60 dB 
for 5 mins. The animals were then tested without any injections in the startle pro software 
for 3 days. The test is highly automated, meaning all parameters are preset by the software. 
The parameters include: 60 seconds acclimation, 10 msec prepulse duration, 3 msec 
prepulse rise, 70 dB prepulse intensity at 3 different frequencies of 4, 12, 20 kHz, 100 msec 
prepulse delay and, 10 msec startle duration, 0 msec rise, startle noise bursts of 70, 80, 90, 
100 dBs, fixed sequence 3->8 seconds inter-trial-interval all summing up to 55 trials (24 
with prepulse stimuli).  
Statistical Analysis 
Acoustic Startle responses evoked by 100-dB startle only (S2-only) intensities 
without prepulses (S1s) establishes a baseline startle amplitude for each mouse. PPI for 
each of the prepulse frequencies was calculated by dividing startle amplitudes with 
prepulse amplitudes by baseline amplitude (S1+S2 trials / S2 only trials). Therefore, a 





8 male CD1 mice were tested using the Med-PC’s Startle PPI software. Animals 
were acclimated to the chambers with 65dB white background noise the first three days 
followed by the three-week testing period, first week without any injections, second week 
with vehicle, 1 mg/kg, and 0.1 mg/kg doses of Haloperidol, and third week with the same 
doses of 7-OH-DPAT.  
Sixteen startle-only noise bursts, eight 70.04+100, eight 70.12+100, eight 70.20+100, five 
70dB noise bursts, five 80dB noise bursts, and five 90dB noise bursts were produced. All 



















Animals were tested at four different startle-only intensities, 70 dB, 80 dB, 90 dB, and 100 
dB, and at three different prepulse + startle intensities (70 dB 4 kHz frequency, 70 dB 12 
kHz frequency, and 70 dB 20 kHz frequency followed by 100dB startle noise. The data 





prepulse stimuli, startle response to startle stimuli reduced significantly. These results are 




Effect of Dopamine Drugs on Prepulse Inhibition 
  
Note. Effect of two different doses of haloperidol(a) and 7-OH-DPAT(b) in startle response 
at three different prepulse frequencies. No significant effects were produced by both the 
drugs. Startle response increased with the increase in prepulse frequency in both the cases, 









Prepulse inhibition is a measure of sensorimotor signaling that is impaired in 
patients with Schizophrenia and thus can be used as a biomarker of the disease. When a 
weaker pre-stimulus precedes the startle stimulus, PPI filters out the irrelevant stimulus 
and decreases the sensory overload. Haloperidol, an antagonist at D2 receptor is used in 
the treatment of positive symptoms of Schizophrenia. In the present study, Prepulse 
inhibition of startle stimuli was measured at various sound intensities and frequencies. 
Haloperidol and 7-OH-DPAT were injected to in the male CD1 mice to observe the effects 
of Dopamine agonists and antagonists on prepulse inhibition. We expected to observe an 
increase in prepulse inhibition with haloperidol and a decrease in prepulse inhibition with 
7-OH-DPAT, but the data showed no such effects. However, in both the studies, a decrease 
in startle response to startle stimuli when preceded by prepulse stimuli was observed 
indicating that all the mice have intact prepulse inhibition and thereby the sensorimotor 
gating.  
There are limitations to this study. Firstly, the major limitation is the ineffectiveness of 
haloperidol and 7-OH-DPAT on prepulse inhibition. In previous studies, haloperidol 
prevented the disruption of PPI induced by dopamine agonists. Though 7-OH-DPAT 
showed a significant disruption of PPI in other studies, in the present study it had no effect 
on Prepulse inhibition. The effect of haloperidol on the disruption of 7-OH-DPAT (if any) 
has not been assessed. Secondly, there are some sex mediated differenced in dopamine 




in male mice, there could be a significant difference in results if female were used for the 





















Niemann Pick Disease Type C 
Introduction 
Niemann Pick Disease Type C is a progressive genetic disorder characterized by 
the lysosomal accumulation of lipids which causes neurodegeneration, dementia, ataxia, 
and death. Cognitive impairments, severe motor deficits, and primary behavioral 
disturbances are some of the other symptoms observed as the disease progresses. In some 
cases of adult onset, psychiatric disorders such as schizophrenia, attention deficit 
hyperactivity disorder, and depression were pre-diagnosed suggesting neural circuitry 
disfunction precede the neurological symptoms.  
Pathophysiology of NPC 
NPC is caused by a mutation in NPC1 gene that encodes for a protein that is in the 
limiting membrane of endosomes and lysosomes. The protein binds cholesterol to its N-
terminal domain and mediates cholesterol trafficking. The mutations in NPC1 gene 
includes small intragenic deletions/insertions, and missense, nonsense, and splice site 
variants that cause the dysfunction of autophagic-lysosomal pathway in cells. This leads to 
the formation of structural abnormalities and ectopic dendrites in mature neurons which 
suggests that lysosomal dysfunction in NPC modifies neuronal structure and function. 
During the developmental ages and after injury, neuronal autophagy and glial phagocytosis 




In addition, autophagic-lysosomal activity inside the axons and in surrounding phagocytes 
is important for the degeneration and removal of axon terminals during developmental 
pruning but in case of NPC and other Lysosomal Storage Diseases (LSDS), lysosomal 
dysfunction alters the process of synaptic pruning and removal of unwanted synaptic 
structures during development. Purkinje cells are hypersensitive to the loss of NPC1 
protein and degenerate earliest and to a greater severity than other neurons in the brain 
which contribute to the development of early neurological symptoms such as clumsiness, 
gait defects, and ataxia. Nevertheless, it is still unclear as to how the NPC1 deficiency 
effects synaptic development at postnatal stages. Presumably, this susceptibility of 
Purkinje cells to early neurodegeneration could possibly be because of intrinsic and/or 
extrinsic pathological events during neurodevelopment caused by NPC1 deficiency. In 
order to understand the underlying mechanisms involved in the early dysfunction and 
degeneration of PCs, it Is important to detect the timeline of pathological changes in the 
cerebellum caused by NPC1 deficiency. In a study with mice with complete NPC1 deletion, 
microglial cells of neuroinflammatory phenotype were recognized as early as two weeks 
of age and at 3 weeks genes associated with immune responses in the cerebellum showed 
a change in their expression. A knockout mouse showed neurological symptoms at as early 
as 4-5 weeks of age which made it difficult to find out if the neuroinflammation was caused 
in response to the absence of NPC1 gene function in microglial cells or a result of PCs 






NPC and Neurological Disorders  
Recent studies presented evidence to the contribution of microglial cells to the 
developmental synaptic pruning defects in several neurological disorders like epilepsy, 
schizophrenia, autism spectrum and fragile X syndrome. Interestingly, NPC in humans 
cause neurological diseases that rapidly develops and progresses during childhood but 
shows no apparent neurological symptoms during early infantile age. In addition to these 
neurological diseases, some cases of juvenile and adult-onset NPC in humans were pre-
diagnosed with psychiatric disorders like ADHD and schizophrenia due to cerebellar 
dysfunction prior to the manifestation of the NPC neurological symptoms. This provides 
the evidence that neural circuitry instabilities precede the loss of neurons in NPC and the 
neurological symptoms which may alter psychomotor behaviors.  
Current Research at Rowan 
Microglial cells have the highest expression of NPC1 gene in brain which is why it 
is important to understand how the NPC1 deficiency influences the proinflammatory 
responses in the microglial cells and the disease progression. The late-onset NPC mouse 
model at our laboratory showed neuroinflammatory responses in the synaptic region of the 
cerebellum (molecular layer) of the brain such as microglial reactivity and monocyte 
infiltration preceding the PCs degeneration. Moreover, PCs were degenerated by active 
engulfing of calbindin and dendrites of PCs by IBA1 and microglia/macrophages which 
suggest that preceding neuronal death, synaptic structures of PCs were targeted and 
removed by phagocytes. Interestingly, by the end of postnatal development and before any 




molecular layer increased which lead to the conclusion that the abnormal development at 
the molecular layer of the cerebellar synaptic structures along with microglial reactivity 
due to NPC1 deficiency synergistically lead to synaptic defects that augment 
neuroinflammatory responses in the cerebellum which precipitate the onset of PCs 
degeneration.  
Recent studies showed that cerebellar microglia have a gene expression that is different 
from the microglia in other regions of the brain. Higher immune defense and 
immunoregulatory genes were observed in healthy microglia obtained from cerebellum 
than in the ones obtained from cortex or hippocampus. This shows that the microglia in 
cerebellum are more immune-vigilant and deficiency of NPC1 in microglia is more 
detrimental in cerebellar microglia than in the microglia from other parts of the brain.  
Prepulse Inhibition in NPC 
Previous studies showed a decreased prepulse inhibition in mice with NPC1nmf164 
mutation compared to the wild type mice due to impaired sensorimotor gating.  
Aim 
The aim of this proposed research is to identify cellular and molecular pathways 
involved in causing and progressing NPC in young patients from which effective 
therapeutic interventions can be designed and tested to prevent or delay the onset of the 
disease and prolong and improve the quality of life of young NPC patients. The first part 
of the research plan was aimed at dissecting the effects of Npc1nmf164 mutation on the 




determine whether the Npc1nmf164 mutation affects developmental axon pruning in the 
cerebellum. Finally, the third aim was to examine whether the mutation causes cerebellar 
synaptic defects and psychomotor behavioral abnormalities before the degeneration of the 
PCs. 
The Npc1nmf164 mouse model is based on the C57BL/6J mouse strain with a point mutation 
in NPC1. This mouse model has a single amino acid change from aspartate to glycine in 
the cysteine-rich luminal loop of the NPC1 protein at position 1005 or bp 3163 and is very 
similar to usually occurring human mutation. The factors that make Npc1nmf164 mouse 
model a valuable model for understanding this disease and its progression are the location 
of this mutation which is like that found in humans, late-onset and slower disease 
progression. Breeding colonies were established for the knockout mice and tests were 
conducted on knockout, heterozygous and wild type offspring on 21/22 day. Typically, in 
humans, for a couple who are both carriers the chances of having an affected child is 25%, 
a child who is a carrier is 50%, and a child who is unaffected is 25%. In NPC like recessive 
genetic disorders, the risk is the same for both male and female offspring.  
Animals 
Heterozygous NPC1nmf164and wild-type C57BL/6J mice, weighing 23-30g at the 
start of experiment were used. Upon arrival to the laboratory, the mice were given free 
access to food and water in a room that was maintained at a constant temperature (21-23°C) 
and humidity (45-50%) on a 12h light-dark cycle. Breeding colonies were thus established, 
and the litter were genotyped on P18 by tail clipping and weaned on P20/21. Gestation 




arrival of the new litter. Behavioral studies were conducted from P21/22 depending on the 
day of weaning.  
Equipment 
Open-Field Locomotor 
 This test was conducted in an apparatus obtained from med associates. It has four 
chambers with cameras mounted on top of each chamber to monitor the movement of the 
mice. All the chambers and the cameras were connected to the computer and run by Any-
maze software. The field was divided into center region and outside regions, and the time 
spent in the two regions was recorded.  
Rotarod 
 This equipment has a horizontal rod that can be set to rotate at different speeds. 
Mice were placed on the rod for 300seconds and the speed and time at which the mice 
tripped off the rod was recorded.  
Procedure 
21/22-day old pups were tested in open field locomotor and rotarod equipment. The 
pups were placed inside the boxes of locomotor equipment and tested for their locomotor 
activity for 30 minutes to find out if there was a difference in movement among various 
genotypes of mutant mice5. NPC1nmf164 mutant mice (knockout) have a delayed acquisition 
of motor skills during development. All the animals in the colony were tested in rotarod 
equipment for their motor skills. The animals were placed on a rod that rotates at a speed 




speed of 40rpm was noted down. At the end of 4 weeks, the animals were euthanized and 
perfused.  
Results 
All the +/- (het), and +/+ (WT) were tested first on rotarod followed by open-field 




Locomotor Activity of NPC Mice 
 
Note. The Total Distance Travelled in Meters in the Open-Field Locomotor Chambers by 
17 +/+, and 22 +/- C57 Mice. +/+ Mice Show Slightly but not Significantly More 






Rotarod Test in NPC Mice 
 
Note. In Rotarod test, +/- and +/+ show an increase in motor activity day-1 through day-3 




NPC is a progressive genetic disorder that causes neurodegeneration leading to 
severe motor and behavioral disturbances. It is caused by a mutation in NPC1 gene that 
codes for a protein that is involved in cholesterol trafficking. NPC1nmf164 mutant mice 
(knockout) have a delayed acquisition of motor skills during development. We 
established breeding colonies to obtain knock-out mice and test them in rotarod, open-
field locomotor and PPI. The breeding colonies produced abundant +/+ and +/- pups. No 
knock-out mice were detected in the colony, hence tests were only conducted in the +/+ 




The study was called to a halt due to a non-compliance issue that raised due to the 





















Synergistic Antihyperalgesic and Antinociceptive Effects of Morphine and MP-III-
024, a Positive Allosteric Modulator at α2GABA and α3GABAA Receptors 
Introduction 
Opioids are drugs that relieve pain. Prescription opioids are used to treat moderate 
to severe pain, but they are also associated with serious side effects like constipation, 
euphoria, and respiratory depression. They are often misused for their euphoric effect. 
Opioids interact with the opioid receptors in the central nervous system and the 
gastrointestinal tract and cause pain relief and constipation, respectively33.  
Classification 
Based on Origin 
Opioids are classified into either endogenous or exogenous opioids. Endogenous 
opioids are the opioids that are produced by the body. There are three endogenous opioids: 
• Beta-endorphin  
• Enkephalin 
• Dynorphin 
Exogenous opioids are not produced within the body. They are further classified into 3 







Classification of Opioids Based on their Origin 
 
 
Based on Opioid Receptors 
There are three receptors at which opioids usually show their effects. They are mu 
(MOP) receptors, delta receptors, and kappa receptors. Opioid receptors are G-protein-
coupled receptors. Only after the discovery of these receptors was a series of endogenous 
opioid ligands discovered in brain extracts. A fourth receptor with opioid-like receptor 









Natural opioids Morphine, Codeine, Thebaine, and Papaverine 
 
Synthetic opioids Methadone, Fentanyl, Pethidine, Alfentanil, Remifentanil, 
and Tapentadol 
 





Clinical Effects of Opioid Receptors  
MOP DOP KOP NOP 
Analgesia Analgesia Analgesia Analgesia 
















Opioid Receptors and their Respective Endogenous Ligands 
Receptor Endogenous ligand 


















Classification of Opioids Based on their Receptor Binding and Affinity 


























Mechanism of Action 
Opioid receptors are coupled to inhibitory G-protein coupled receptors Gαi or Gαo. 
Opioids cause two types of inhibitions; Presynaptic or Postsynaptic.  
Presynaptic inhibition: G protein is made of 3 subunits, α, β, and γ subunits. When an 
opioid bind to the receptor, a number of structural and molecular changes occur at the G 
protein and the α subunit dissociates from βγ subunit. βγ subunit interacts with the voltage 
gated calcium channels on the presynaptic neuron that help in releasing the 
neurotransmitter and prevents them from opening. This inhibits the action potential from 
propagating from presynaptic neuron to postsynaptic neuron.  
Postsynaptic inhibition: When opioids bind to the opioid receptors on the postsynaptic 




coupled potassium channels, opens them and the potassium moves out of the cell. When a 
neurotransmitter binds to the receptors on postsynaptic neuron and opens Na+ channels 
(depolarization), the positive charge that is brought about by the Na+ ions is negated by the 
K+ ions moving out thus causing hyperpolarization and inhibiting the action potential from 
further propagation.  
Gαi role: The α subunit of the G protein is involved in inhibiting the cAMP production. 
Adenylyl cyclase is an enzyme, present in the plasma membrane, converts ATP to cAMP 
which activates cAMP dependent protein kinases. Protein kinases are made of regulatory 
subunit and catalytic subunit. cAMP binds to the regulatory subunit and gets dissociated 
from the catalytic subunit. The catalytic subunit then phosphorylates the neuronal proteins 
and channels which either activates or inhibits them. This in turn starts some signaling 
pathways and stops some. Gαi/o interacts with the adenylyl cyclase and inhibits it converting 
ATP to cAMP.  
β-Arrestin signaling: β-Arrestin proteins play a significant role in signal transduction at G 
protein-coupled receptors. β-Arrestins regulate especially Mu opioid receptor signaling by 
receptor desensitization. Desensitization occurs by phosphorylating the GPCRs by 
serine/threonine kinases called G protein coupled receptor kinases. The phosphorylated 
GPCRs recruit β-Arrestin which blocks G-protein mediated signaling either by 
desensitizing the receptors or internalizing the receptors34. Regulation of GPCRs by β-
Arrestin is multifaceted and the other way in which they regulate is by activating the 
mitogen-activated protein kinase (MAPK) downstream signaling cascade which inhibit G 




Analgesic Mechanism of Action 
There are two pain pathways, ascending and descending. Ascending pathway sends 
pain signals to the brain while descending pathway blocks the ascending pathway.  
Ascending pathway: the pain stimulus gets propagated from the site of pain through the 
primary sensory neuron which meets secondary sensory neuron in the spinal cord. The 
secondary sensory neuron passes through the brain stem into the thalamus which processes 
the sensory information and synapses with tertiary neurons that activate brain cortex that 
is involved in giving meaning to the pain.  
Descending pathway: The neurons in the descending pathway are normally inhibited by 
the GABA neurotransmitter that are released from the inhibitory interneurons in the brain 
stem. In response to pain certain neurons release endogenous opioids that bind to the 
inhibitory interneurons in the descending pathway and prevents GABA neurotransmitter 
release. Without GABA, the neurons in the descending pathway are no longer inhibited 
and the endogenous opioid releasing interneurons in the spinal cord get activated and 
inhibit the pain signal propagation between primary and secondary neurons of the 
ascending pathway.  
Exogenous opioids act the same way endogenous ligands do in activating the descending 
and inactivating ascending pathway.  
Opioid receptors are also present in the ventral tegmental area, and respiratory center which 
upon binding with opioids causes addiction and respiratory depression, the two main side 





Mesolimbic pathway, also called the reward pathway connects ventral tegmental 
area of the midbrain to the ventral striatum of the basal ganglia of the forebrain. Nucleus 
accumbens and olfactory tubercle make up the ventral striatum. Nucleus accumbens plays 
a pivotal role in the reward pathway. Dopaminergic neurons that extend from the ventral 
tegmental area to the nucleus accumbens are regulated by GABAergic interneurons that 
have opioid receptors. When opioids bind to the opioid receptors on the GABAergic 
interneurons, GABA inhibition of dopamine release is stopped as a result of which 
excessive dopamine is released which activates reward pathway inducing pleasure. After 
repeated use of opioids, a direct association is developed between opioid and pleasure 
which is called as drug liking.  
Tolerance Mechanism 
It is a condition when body requires more drug to produce same effects after 
repeated use of the drug. Repeated Opioid use deplete the cAMP reserves in the body. To 
achieve homeostasis and compensate for the anticipated loss of cAMP, neurons 
preemptively produce more cAMP which makes the neurons hyperactive. Opioid intake 
followed by this increase, decreases the cAMP as expected but to a level that is within the 
normal range. For the opioids to produce effects similar to those in the early stages, the 
dose needs to be increased. Other factors that contribute drug tolerance are receptor 
phosphorylation that changes the receptor shape, receptor internalization, decrease in 
number of receptors available for ligand binding, and receptor-effector uncoupling which 





Withdrawal symptoms are due to the increased cAMP levels in the body that 
overfires the neurons. cAMP levels are spiked in order to compensate for the loss of it upon 
opioid intake. In case of no drug present in the body, the cAMP that is produced by the 
body preemptively (to achieve homeostasis like discussed previously) overfires the 
neurons causing withdrawal symptoms. Ventral tegmental area, locus coeruleus, and 
intestines are the most affected areas of the body.  
Locus coeruleus is the site for norepinephrine synthesis in the brain. Locus coeruleus is 
responsible for alertness or wakefulness in humans or causing psychological stress. It also 
activates the sympathetic nervous system or fight or flight response of the body. Activated 
sympathetic nervous system produces sweating, pupil dilation, increased heart and 
breathing rates. Opioid use produces the opposite effects, while withdrawal symptoms 
exaggerate the normal functions of locus coeruleus. When opioids bind to the opioid 
receptors in locus coeruleus, common side effects of opioid use like drowsiness, sedation, 
dry skin, pinpoint pupil, and decreased heart and breathing rate are observed. During 
withdrawal, the over firing neurons cause jitteriness and insomnia, anxiety, excessive 
sweating, wide dilated pupils, and rapid heart and breathing rate.  
Opioid receptors on the neurons that innervate and control gut movement, when bound by 
opioids cause constipation, a common side effect observed with opioid use. During 
withdrawal, gut movement becomes rapid and expels feces even before enough water is 




In the ventral tegmental area, the GABAergic interneurons that keep the dopaminergic 
neurons in check become tolerant to opioids and regain their ability to inhibit dopaminergic 
reward pathway even in the presence of opioids which causes the feeling of discomfort. To 
avoid these consequences, patients continue to use opioids and fall into the category of 
opioid use disorder.  
Overdose Mechanism 
Breathing is controlled by Pre-Botzinger complex in the brain stem. This complex 
sends signals rhythmically to diaphragm and other respiratory muscles that enables 
breathing. When breathing is stopped by the person for whatever reasons, the feedback 
loop that has chemoreceptors detect increased carbon dioxide levels and decreased oxygen 
levels in the blood and activates Pre-Botzinger complex that forces breathing. These 
chemoreceptors and Pre-Botzinger neurons have opioid receptors and at high opioid doses, 
they get shut down and the complex no longer forces the person to breath and is followed 
by death.  
Naloxone is an opioid receptor antagonist that binds and prevents morphine from binding 
to the receptors thus preventing respiratory depression.  
Uses of Opioids 
Analgesia 
Opioids are generally prescribed in the management of severe acute or chronic pain. 
More than 100 million people in the United States suffer from acute and chronic pain and 




effectively against both cancer and non-cancer pain. Intravenous opioid analgesics are used 
to heal neuropathic pain like central pain, postherpetic neuralgia, and neuropathic pain 
while oral opioid analgesics are effective against neuropathic, musculoskeletal, and other 
non-cancer pain37. Morphine alone can manage severe cancer pain in almost 85% of the 
patients. Combination therapy in the treatment of pain seems promising.  
Edema 
Morphine is a vasodilator and can be used in the treatment of pulmonary edema38. 
Cardiogenic pulmonary edema is a condition in which the left ventricle cannot pump blood 
efficiently out of the heart and builds up pressure. Morphine helps by acting as a vasodilator 
and reducing hydrostatic pressure by lowering preload and afterload.  
Diarrhea 
Loperamide is an opioid agonist that acts like morphine and decreases the tone of 
the longitudinal and circular smooth muscles thereby decreasing the peristaltic movement. 
This increases the duration the material stays in the intestine and the water absorption from 
the feces39. Opioids can also be used in the treatment of Irritable Bowel syndrome with 
Diarrhea (IBS-D). Although there is no effective method available to treat IBS-D, opioids 
can help in alleviating the symptoms. Eluxadoline is a Schedule IV drug approved by FDA 
to manage IBS-D associated symptoms. The drug has a mixed pharmacology. It is an 
agonist at MOR, and KOR, and antagonist at DOR. Since Eluxadoline acts locally by 






Opioids act centrally by suppressing the cough center that is in the medulla 
oblongata in the brain stem. Opioids are the only effective centrally acting anti-tussive 
drugs that act through MOR and KOR agonism. Codeine is effective against acute and 
chronic cough. Dextromethorphan is the most used anti-tussive that is as effective as 
codeine. Hydrocodone is another opioid drug that is used as an anti-tussive, but it is only 
available as a combination drug in the USA. The use of this drug with antihistamine drugs 
often enhances the sedative effects of the drug due to which there is a limit to the maximum 
dose a patient can take. Hydrocodone has fewer gastrointestinal side effects and is as 
effective as codeine making it the drug of choice for cough41. Prescribing opioids as an 
anti-tussive to patients below 18 years of age is not recommended by FDA42.  
Anesthetic 
Opioids are widely used as anesthetics in major surgeries, especially those 
involving cardiovascular disease patients. Opioids do not cause cardiac depression making 
them the drug of choice for inducing anesthesia in patients with cardiovascular diseases43.  
Adverse Effects 
The major adverse effects associated with opioids use is respiratory depression, 
sedation, constipation, and bradycardia. Tolerance, hyperalgesia, dependence, and 
immunologic effects, hormonal change, sleep disturbances, abuse, and addiction are other 






Opioids bind to the receptors located in the respiratory center or Pre-Botzinger 
complex in the brain stem and induce respiratory depression. This opioid induced 
respiratory depression initiates cardiorespiratory arrest with subsequent hypoxia and 
hypercapnia resulting in fatalities. Mortality in opioid addicts that overdose on morphine 
and heroin usually die of respiratory depression and respiratory failure. 
Sedation 
It is the second most observed adverse effect associated with opioid use. Opioids 
are the primary choice of drugs used in the management of pain in hospitalized patients. 
Sedation is a common adverse effect during first 24 hours of opioid therapy. To combat 
this effect, opioids are often prescribed with other drugs like methylphenidate, which is a 
first-line therapy for reducing sedation45. 10-15mg of methylphenidate has been observed 
to reduce drowsiness significantly in cancer patients. Simultaneously, reducing opioid 
doses without reducing analgesic effect may also be possible. Other drugs like 
dextroamphetamine, donepezil, modafinil, and caffeine can be used to reduce opioid 
induced sedation46.  
Constipation 
40-60% of the non-cancer patients receiving opioids experience opioid induced 
constipation.  Patients also develop other GI side effects like nausea, vomiting, bloating in 
the stomach, abdominal pain, and straining. Stimulants like Senna or Bisacodyl are 




to prevent constipation. Lubiprostone increases fluid secretion in the GI tract by activating 
type 2 chloride channel increasing the tone and peristalsis, accelerating the small bowel 
and colonic transit times. Methylnaltrexone bromide, a peripherally acting opiate 
antagonist is used in the treatment of opioid induced constipation. It does not cross the 
Blood Brain Barrier to induce symptoms of opioid withdrawal making it the most superior 
agent among all the available agents. Naloxegol, alvimopan, and naldemedine are approved 
for the treatment of OIC in non-cancer pain patients47.  
Cardiac Effects 
Opioids cause bradycardia and vasodilation. Opioids when administered with other 
medications like benzodiazepines, may decrease cardiac function. Methadone and 
Buprenorphine are known prolong QTc, especially in patients at high risk for QTc 
prolongation. Morphine, hydromorphone, hydrocodone, and meperidine decrease systemic 
vascular resistance and blood pressure by releasing histamine48.  
Tolerance 
Opioid tolerance occurs when the same amount of drug shows reduced 
responsiveness and is manifested as the need to use an increasing dose to achieve a desired 
effect49. Increased doses of opioids given to counter tolerance can result increased opioid 
associated adverse effects and opioid induced hyperalgesia. Factors that dictate the 







Opioids induce hyperalgesia, a state of increased pain sensitivity following long-
term use of high-dose opioids. It occurs when neoplastic modifications occur in both 
peripheral and central nervous system. There are no well-established molecular 
mechanisms as to how Opioid induced hyperalgesia occurs, but it could be due to the 
molecular adaptations in MOR-expressing neurons that change the interaction between 
cells and activate the independent oppositional system. In addition, opioid induced 
apoptosis could also contribute to the development of hyperalgesia. This sensitization is 
pain is a paradoxical response and the pain experienced in OIH can be very close to the 
patient’s original pain50.  
Immunologic Effect 
Morphine has been observed to decrease the effectiveness of both natural and 
acquired immunity in animal and human studies by interfering with the intracellular 
pathways involved in immune regulation. Not all the opioids have same 
immunosuppressive effects51. Morphine, codeine, methadone, fentanyl, sufentanil, and 
remifentanil produce strong immunomodulating effect while oxycodone, tramadol, 
buprenorphine, and hydromorphone produce weak immunomodulating effect. In selective 
vulnerable populations like elderly or immunocompromised patients, opioid mediated 
immune effects could be particularly risky. The least immunosuppressive opioid is 






Endocrinopathy (OE) is a term used to describe hormone problems. Opioids induce 
endocrinopathy by affecting different hormones like testosterone, estrogen, luteinizing 
hormone, gonadotropin releasing hormone, dehydroepiandrosterone, and 
adrenocorticotropin and corticotropin-releasing hormone, and cortisol. Opioids affect men 
and women differently. In men, sexual disorders like erectile dysfunction, decreased libido, 
depression and decreased energy levels are common side effects. Testosterone levels drop 
significantly one to four hours after acute administration of opioids and takes around 24 
hours to return to normal levels. Chronic administration of opioids results in tonic decrease 
in both total and free testosterone levels53. In women, opioids cause depression, 
dysmenorrhea, sexual dysfunction, and potentially reduced bone mineral density54.  
Sleep Disturbances 
Disorders of sleep-wake cycles, disorders of initiating and maintaining sleep. 
Dysfunction associated with sleep stages and partial arousals are some of the sleep 
disturbances that are associated with long-term opioid use such as in cancer patients55,56. 
Studies showed that opioids can increase the number of sleep-wake transitions and reduce 
the sleep time and efficacy57. Opioids alter the balance of neurotransmitters that regulate 
sleep like serotonin, acetylcholine, noradrenaline, histamine, dopamine, GABA, melatonin 







Opioids have high abuse potential due as they induce euphoria and reduce negative 
dysphoric moods59. Addiction is a chronic, relapsing disorder that is characterized by 
strong desire to take the drugs even when medically unnecessary. Prescription opioids can 
also cause addiction in people60. 
The Opioid Epidemic 
The Opioid epidemic is a major health concern occurring from the over-prescription 
of opioids to relieve pain, increase in opioids use/abuse/overdose significantly impacting 
patient health and economy. According to the center for disease control and prevention, 
there are three different waves in the modern American opioid epidemic that raised the 
mortality due to opioid overdose. The first wave was in 1990s, when opioids were 
prescribed increasingly. The second wave was in 2010, when heroin caused large number 
of overdose deaths. The third wave began in 2013 due to significant deaths due to synthetic 
opioid overdosing, mainly those that were illicitly manufactured like fentanyl (IMF)61,62. 
In 2016, 11.5 million Americans were misusing opioid prescriptions, more than 2.1 million 
people had a diagnosable opioid use disorder and more than 42,000 died from opioid 
overdosing. In 2017, US department of Health and Human Services declared a public 
health emergency for this opioid crisis following 70,000 overdose deaths63. Over the last 
two decades, hundreds of thousands of lives have been lost and millions of people and their 
families have been affected by opioid epidemic. Opioid misuse, abuse, and overdose have 





Opioid addiction has limited treatment options. Recovery requires Behavioral 
therapy and Pharmacotherapy either individually or in combination along with counseling 
and support64,65. Treatment is generally started with counseling, opioid replacement 
therapy, and gradual discontinuation of the drug. Sudden discontinuation of the drug causes 
severe withdrawal symptoms in which case drug detoxification is the only choice for the 
physicians66.  
New Analgesia and Strategy 
NSAIDs and opioids are used in the treatment of pain. NSAIDs show weak 
analgesic activity than opioids and act peripherally. Opioids act both centrally and 
peripherally owing to their both central and peripheral side effects33. High abuse potential 
of opioids raises the need for new treatment regimens and strategies in pain management.  
Methods to Determine Analgesic Activity 
To test analgesic agents, animals are subjected to nociceptive/painful stimuli prior 
to administering an analgesic. The painful stimuli generates a response like jumping, 
licking, shaking of the paws, skin twitch, tail flick, or flight which is indicative of painful 
sensations. Popular methods for determining analgesic activity are 
Writhing Test 
Irritants like Phenylquinone or acetic acid are injected into the mice or rats in their 
abdominal regions to induce pain and cause writhing. This is followed by the injection of 




significantly67,68. This test is suitable to test for the analgesic profile of the peripherally 
acting painkillers like chlorpromazine and meprobamate. The major drawback with this 
test is that it is difficult to evaluate the analgesic duration as the frequency of writhing 
decreases over time69,70.  
Hot Plate Test 
It is a thermal pain sensitivity test in which the rodents are placed on a hot surface 
that is maintained at a specific temperature for a specific time frame and observed for 
nocifensive activity like paw licking, fluttering, and jumping71. Upon injecting the animal 
with analgesic drug, the latency to respond on hot plate increases indicating that the drug 
is showing analgesic activity. Hot plate is a tricky test comparatively to other thermal 
assays as rodents show very complex and subtle behavioral response72.  
Von Frey Test 
This is a mechanical pain sensitivity test. Animal is subjected to noxious stimulus 
using a 50mm long filament of varying diameters. The animal is placed on an elevated 
mesh screen and poked with filaments to different diameters to induce pain73. If the animal 
withdraws the paw or starts licking or shaking the paws, it means the animal is feeling pain. 
The exact force of the fiber is determined by its thickness. After injecting the analgesic 
drug, the latency to respond to this painful stimulus increases indicating the analgesic 






Tail Flick Test 
This is one of the most common nociceptive assays. In this technique, heat is 
applied to the animal’s tail and the pain sensitivity is determined by measuring the tail flick 
latency75. If this latency is prolonged upon administration of the test drug, it indicates that 
the drug has analgesic properties. The major drawback with this technique is that spinal 
transection above the lumbar fails to block the tail flick response, thus it may not be 
measuring the pain but the spinal nociceptive reflex76.  
Formalin Test  
This test is used to measure clinical pain due to injury. Dilute solution of formalin 
is injected onto the planter surface of the rodent’s hind paw and is observed for rodent’s 
stereotypical behavior such as flinching, licking, and biting of the affected hind paw which 
are used as the measurements of inflammatory pain. These effects last for 15-60minutes77. 
This method is preferred over other techniques because this model is useful to measure 
both acute and tonic pain78 that affects inflammatory, neurogenic, and central mechanisms 
of nociception79,80.  
GABA Receptors 
γ-aminobutyric acid is a neurotransmitter that has inhibitory activity in the CNS. 
Inotropic GABAA receptors are one of the two major classes of GABA receptors that 
include various αβγ2 isoforms assembled from varying α, β, and γ subunits with 
differential signaling and expression patterns. Benzodiazepine-like drugs act as positive 




receptors81. These receptors are distributed within the CNS with α2GABAA and 
α3GABAA especially expressed in the Dorsal Horn Spinal pathway that is important to 
nociceptive transmission82. Previous studies have demonstrated that intrathecally 
administered benzodiazepines mediate antihyperalgesic effects via α2GABAA and 
α3GABAA receptors at the level of the spinal cord
83,84,85. Moreover, systemically 
administered compounds with PAM activity at α2GABAA and α3GABAA receptors 
showed reduced activity at supraspinally located α1GABAA receptors which mediate 
side-effects of clinically used, commercially available benzodiazepines like 
diazepam83,86,82,87,88.  
μ-opioid receptors are co-expressed with α2GABAA and α3GABAA receptors in 
nociceptive pain pathways which raises the possibility for interactive or combination 
effects88. If supra-additive or synergistic effects are detected on endpoints related to pain 
reduction, combination therapy may be useful to treat pain. A recent benzodiazepine-type 
compound methyl 8-ethynyl-6- (pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a] [1,4]diazepine-
3-carboxylate (MP-III-024), with GABAA PAM effects was synthesized that displayed 
functional selectivity for α2GABAA and α3GABAA receptors over other GABAA 
receptors like α1GABAA and α5GABAA. This selectivity produced antihyperalgesic 
effects with no off-target effects as observed with operant responding and locomotor 
activity88. These data are along the same lines with other structurally related α2GABAA 
and α3GABAA preferring ligands, HZ-166
86 and KRM-II-8189. MP-III-024 is a close 
analog of HZ-166 which showed non-sedating anxiolytic activity in rhesus monkey and 




course and duration of action compared to morphine, a prototypical μ-opioid receptor 
agonist making it ideal for combination studies,88. In the present study, dose addition 
analysis was used to assess α2GABAA / α3GABAA receptor-opioid interactions. 
Materials and Methods 
CD-1 mice 10 weeks of age were obtained from Charles River Laboratories. 
Animals were housed in a vivarium that is maintained at a constant temperature and 
humidity with constant access to air and water, under a 12h light/dark cycle (lights on at 
7:00 AM). Mice were housed in groups of four in polycarbonate cages with ad libitum 
food and water and enrichment provided by paper Bio-Huts and/or nestlets. No 
experiments were conducted for 2 weeks upon their arrival to habituate them to the 
colony room environment. Mice were handled for 2 days prior to the initiation of 
experiments. Typical testing period was between 11:00 AM and 3:00 PM. Care of 
animals was taken in accordance with the guidelines of the Institutional Animal Care and 
Use Committee of Rowan University and all testing adhered to the “Guide for the Care 
and Use of Laboratory Animals” (National Research Council, National Academy of 
Sciences, Washington, D.C., USA, 2011). 
Animals 
CD-1 laboratory mice are used in biomedical and pharmaceutical research. They 
are the progeny of nine Swiss mice, two male and seven female albino mice that were 
imported to the USA by Dr. Clara Lynch of the Rockefeller Institute for Medical 




Experiments were started when the animals were 35 days old and were weighing 
approximately 22-25 g. The animals were aggressive the first few days of handling and 
gradually got accustomed to human handling.  
Drugs 
Methyl 8-ethynyl-6-(pyridin-2-yl)-4Hbenzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate (MP-III-024), the novel benzodiazepine analog was synthesized at the 
Department of Chemistry and Biochemistry at the University of Wisconsin-Milwaukee. 
Morphine was purchased from Sigma-Aldrich. 0.5% methyl cellulose dissolved in 0.9% 
NaCl was used as a vehicle to suspend the drugs and was administered intraperitoneally 
in a total volume of 10 ml/kg body weight.  
Hot Plate Testing 
A 25.3 × 25.3 cm measuring hot plate analgesia meter was used to assess 
antinociception. The plate was maintained at 56 ± 0.1°C. The antinociceptive response 
was measured by assessing the latency to lick or shuffle or flutter the hind paw(s) and/or 
jump from the hot plate surface. To prevent tissue damage, a predetermined cutoff time 
of 20 s was defined as a maximal response. The antinociceptive response was measured 








The hot plate analgesia meter (Columbus Instruments, OH) for small laboratory 
animals were used for this analgesic test. (Figure 9) The hot plate could continuously 
provide 55 °C temperature on an aluminum surface, with a digital built-in thermometer to 
maintain surface temperature to 0.1 °C precision and a timer with a 0.1 sec precision. The 
square shaped surface plate was enclosed by a clear acrylic cage to confine animals 
during testing. Pushes on start/stop button related to the timer, which displayed the time 
on the screen which was recorded manually90.  
Procedure 
The hot plate was maintained at 56 °C. Animals were placed on the surface of the 
hot plate and observed for certain behavioral changes like paw licking, flutter, and 
jumping, which indicates animal’s pain feeling. Latency time to respond to the stimuli 
after placing the mice on the hot plate provided a threshold level. Two baseline studies 
were conducted prior to injecting the animals with the drug. After weighing the animals, 
testing drug was administered and animals were placed on hot plate in 15, 30, 45, 60 
and/or 75/90 minutes time intervals to measure the latency time. The mouse was 
immediately taken off the hot plate if any behavioral changes were observed and the time 
was recorded. Animals were removed from the hot plate after 20 seconds even though no 
considerable behavioral change was observed to avoid tissue damage. Animals that 






 The anti-nociceptive effect for each dose was calculated as the % of the Maximal 
Possible Effect (% MPE) using the following formula:  
%MPE =  (
Latency time after drug administration − Mean latency time of baseline studies
{Maximal latency time (20) − Mean latency time of baseline studies}
) X 100                         
 
Von Frey Test 
A subcutaneous injection of 0.06 mg Zymosan A suspended in 20 µl 0.9% NaCl 
was given into the plantar surface of the right hind paw to induce inflammation and study 
antihyperalgesia and the e non-injected left hind paw was used as control. 24 hours after 
the Zymosan A injection, mechanical sensitivity was measured by applying von Frey 
filaments of increasing stiffness (5-26 g) to mid plantar surface of the hind paws until the 
filament bends. Paw withdrawal response is indicative of positive response and the 
mechanical threshold is defined as the minimum force necessary to elicit a positive 
withdrawal response.  
Apparatus 
The apparatus consists of a mesh screen that is mounted on a stand at eye level. 
Animals are placed on top the mesh and poked from below with von Frey filaments of 
increasing stiffness of 0.008-300 g to determine the threshold that produces a hind paw 
withdrawal response. The minimum gauge von Frey filament that causes a withdrawal 





Each mouse was weighed, and baseline studies were conducted prior to injecting 
drugs. Testing drug was injected, and the animals were placed on the wide gauge, wire 
mesh surface in 15, 30, 45, 60, and/or 75/90 minutes time intervals and von Frey filaments 
of increasing stiffness were applied until the filaments were seen to bend. If the same 
filament made the mouse respond by flicking its paw away 3 times, the diameter of the 
filament was recorded, and the process repeated with increasing gauges of von Frey 
filaments that have different stiffness until stimulation forced a hind paw withdrawal.  
Statistical Analysis 
 The mechanical threshold following drug administration was normalized to the 
baseline measurement of the non-injected left hind paw and expressed as a percentage of 
the maximal possible effect (%MPE) from the following formula: 
%𝑀𝑃𝐸 = (
𝑝𝑜𝑠𝑡 𝑑𝑟𝑢𝑔 𝑟𝑖𝑔ℎ𝑡 𝑝𝑎𝑤 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 (𝑔) − 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑟𝑖𝑔ℎ𝑡 𝑝𝑎𝑤 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑(𝑔)
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑙𝑒𝑓𝑡 𝑝𝑎𝑤 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 (𝑔) − 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑟𝑖𝑔ℎ𝑡 𝑝𝑎𝑤 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 (𝑔)
)  𝑋 100 
Isobolographic and Dose-Addition Analysis  
Graphical and statistical approaches were used to assess the interaction between 
MP-III-024 and morphine. With the use of isobolograms, graphical approach made a 
distinction between sub additive, additive or synergistic interactions. In the current study, 
isobolograms were constructed by plotting and connecting the ED50 of MP-III-024 on 
abscissa with the ED50 of morphine on ordinate to obtain an additivity line. The additivity 




III-024 alone. Dose pairs that fell below the additivity line suggested ED50 was reached 
with lesser quantities of the drugs which was suggestive of synergism and the experimental 
points representing dose pairs that fell above the lone suggested subadditivity.  
Drug interaction can be analyzed in different ways. Among them, a comparison of the ED50 
values for each mixture with the predicted additive ED50 values is a good way to determine 
the potency of the prospective combination drug. ED50 values for each mixture can be 
represented by Zmix and predicted additive ED50 values can be represented by Zadd
91. The 
total drug dose of combined MP-III-024 and morphine that produces a 50% maximum 
possible effect is called Zmix. If two drugs, e.g., morphine and MP-III024 added together 
in a specific ratio have no sub- or supra-additive effects, the predicted additive response 
can be measured by a predicted ED50 (Zadd). In this mechanical sensitivity assay, if both 
drugs were effective equally, an equation Zadd = fA + (1 - f)B can be used to calculate 
Zadd values individually. In that equation, A is the ED50 for MP-III-024 alone, B is the 
ED50 for the morphine alone, and f is the fraction. For determining the proportion of MP-
III-024 in each mixture equation fA/[fA + (1 - f)B] can be used. This study examined 
effects produced by mixtures in which f = 0.25, 0.5, and 0.75. When f = 0.25, the mixture 
contains a proportion of [A/(A + 3B)] MP-III-024 and a mixture ratio of [(A/B)/3] parts 
MP-III-024 to one-part morphine; f = 0.50 leads to a proportion of [A/(A + B)] MP-III-024 
in the mixture and a mixture ratio of (A/B) parts MP-III-024 to one-part morphine; and f = 
0.75 leads to a proportion of [A/(A + B/3)] MP-III-024 in the mixture and a mixture ratio 




Isobolograms were constructed to determine analgesic properties of morphine alone or in 
combination with MP-III-024 in hot plate and von Fret test. In combination study, upon 
plotting the ED50 on isobologram, three different cases were observed. Points representing 
dose pairs can be on the additive line or lower-left side or upper-right side. If the points fall 
on the additive line, no significant effects are possible of that combination. If the points 
fall on the upper-right side, subadditive or counterproductive effects. If the points fall on 
the lower-left hand side, supra-additive or synergistic effects are possible of that 
combination. Upon testing with different ratios of the mixture in von Frey and hot plate, a 
slight leftward shift of the ED50 values on isobologram were noticed.  
Open-Field Locomotor Test  
To test the effect of MP-III-024 on locomotion, an open field locomotor test was 
conducted in drug naïve CD-1 mice. A cumulative dosing strategy was used in this 
experiment. 3.2 mg/kg, 6.8 mg/kg. 8.0 mg/kg, and 14 mg/kg of morphine alone and MP-
III-024 alone tests were conducted followed by 1:0.94 ratio of morphine to MP-III-024 











Morphine and MP-III-024 in Von Frey and Hot Plate Technique 
 
Note. Dose- effect curves of analgesic properties of morphine and MP-III-024 in von Frey 
technique (left) and Hot plate technique(right). Morphine and MP-III-024 showed 
effectiveness in the von Frey test. MP-III-024 induced antinociception comparable to 
morphine. In the hot plate technique, Morphine showed a dose dependent effect, while MP-
III-024 was with no effect. 
 
 
Figure 10 demonstrates the dose response curves for morphine alone and MP-III-024 alone 
in both the hot plate and von Frey procedures. In the von Frey test, the right hind paw that 
was injected with Zymosan A showed reduced mechanical sensitivity relative to the non-
injected left hind paw whose withdrawal threshold was unaffected (data not shown). In this 




mechanical sensitivity as expressed as %MPE. A statistical test for parallelism revealed 
that the morphine and MP-III-024 dose-effect curves were parallel (p < 0.05). These 
relative potency values were used to determine relative proportions of the compounds used 
in subsequent studies assessing MP-III-024/morphine mixtures. In the hot plate test, 
Morphine produced a dose-dependent increase in the latency to respond to the thermal 
stimulus while MP-III-024 was without effect in this assay. Thus, relative potencies 
determined in the von Frey test were used to determine the relative proportions of the 
























Note. Dose-effect curves of morphine alone and in combination with MP-III-024 in the 
assay of mechanical hyperalgesia and in the assay of thermal nociception b. Abscissae, 
cumulative dose of morphine in each mixture in mg/kg. Ordinate, antihyperalgesic (left) or 
antinociceptive (right) effects of each drug expressed as percent maximum possible effect. 









Isobolograms for MP-III- 024/Morphine Mixtures in the Assay of Mechanical and Thermal 
Hyperalgesia  
Note. Isobolograms for MP-III- 024/morphine mixtures in the assay of mechanical 
hyperalgesia (a) and in the assay of thermal nociception (b). Abscissae, ED50 value for 
morphine in mg/kg. Ordinate, ED50 value for MP-III- 024 in mg/kg. Each point shows the 









The Comparison of Locomotor Activity in Mice Injected with Morphine, MP-III-024, and 
Morphine+MP-III-024.  
 
Note. Figure 13 demonstrates the locomotor activity in mice when injected with morphine 
alone, 0.94:1 ratio of MP-III-024 and morphine, and MP-III-024 alone. The curves indicate 










Morphine and MP-III-024 showed a dose and time-dependent reduction in 
mechanical sensitivity in von Frey procedure while in the hot plate procedure only 
morphine was observed to be effective.  
1:0.94 combination mixture of morphine and MP-III-024 demonstrates an interaction that 
is synergistic in activity in both hot plate and von Frey procedures.  
Variations in withdrawal response is an important tool used to assess changes in the tactile 
sensitivity in mouse models of pain and inflammation. Nociceptive behaviors like paw 
licking, flutter, and jumping and increased response latency following drug administration 
was observed in hot plate technique and interpreted as an antinociceptive response. In von 
Frey test, mechanical sensitivity induced by Zymosan A injection was reduced by each 
compound and dose indicating the antinociceptive response. The two techniques showed 
different effects for both the drugs but in combination, a synergistic effect raised the 
possibility for a new combination of analgesics that could be used in lower doses and obtain 
higher efficacy. Locomotor studies reveal the potential use of MP-III-024 as an analgesic 
that has similar potency, time course and duration of action as morphine but with 
significantly fewer adverse effects.  
There are some limitations to this study. Firstly, all the tests were conducted in male mice. 
Since there are sex-mediated differences in opioid signaling and expression, if the tests 
were conducted in female mice the effect of combination study might have turned out to 




experiments were conducted during the day. The inactive part or the night part of the mouse 
diurnal cycle may provide variable opioid receptor expression and opioid receptor 
activation itself can change the circadian rhythms. If these tests were performed during the 
dark cycle, there is a possibility that it could have yielded different results.  
We aim to test GABAA PAMs such as HZ-166, or MP-III-080, and MP-III-024, in 
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